Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Preventing Low Calcium Levels After Thyroid Surgery with Preoperative Cholecalciferol Supplementation for Patients Undergoing Total Thyroidectomy

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial focuses on the condition known as hypocalcemia, which can occur after a surgical procedure called thyroidectomy. A thyroidectomy is a common surgery where the thyroid gland is removed. After this surgery, some patients may experience low levels of calcium in their blood, known as hypocalcemia, which can cause discomfort and require longer hospital stays. The study is investigating whether taking a supplement called cholecalciferol, which is a form of vitamin D, before the surgery can help reduce the chances of developing hypocalcemia afterward.

The treatment being studied is an oral solution called UVEDOSE 100,000 UI, which contains cholecalciferol. Participants in the study will receive this supplement before their thyroidectomy to see if it helps their bodies respond better to the changes in calcium levels after the surgery. The study aims to assess the effect of this pre-operative supplementation on the occurrence of hypocalcemia following the surgery.

Throughout the study, participants will be monitored for signs of hypocalcemia, such as tingling in the fingers or around the mouth, and their calcium levels will be checked. The study will also look at how long participants stay in the hospital, any side effects they experience, and whether they need additional treatments for low calcium levels. The goal is to determine if pre-operative cholecalciferol supplementation can improve recovery and reduce complications after a thyroidectomy.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be required to provide written informed consent. This means you agree to participate after understanding the study's purpose and procedures.

    You must be at least 18 years old and scheduled for a total thyroidectomy, which is a surgery to remove the thyroid gland.

  2. Step 2

    Pre-operative supplementation

    Before your surgery, you will receive a supplement called cholecalciferol, which is a form of vitamin D. This is to help your body respond better to changes in calcium levels after surgery.

    The supplement is provided as an oral solution called UVEDOSE 100 000 UI. You will take this by mouth as directed by the study team.

  3. Step 3

    Surgery and immediate post-operative period

    You will undergo a total thyroidectomy. After the surgery, your calcium levels will be closely monitored to check for hypocalcemia, which is a condition where calcium levels in the blood are low.

    The study will measure both serum (blood) calcium levels and any symptoms you might experience, such as tingling in the fingers or around the mouth.

  4. Step 4

    Monitoring and follow-up

    For the first 15 days after your surgery, your calcium levels and any symptoms will be monitored. This includes checking for signs like muscle spasms or numbness.

    If necessary, you may receive additional treatment, such as calcium gluconate, to manage low calcium levels.

  5. Step 5

    Evaluation of outcomes

    The study will evaluate the duration of your hospital stay and any adverse events, which are unexpected medical issues that might occur.

    Your vitamin D levels will be measured before and after the surgery to assess the effectiveness of the cholecalciferol supplementation.

Who can join the trial?

4 criteria

  • Patient must be 18 years or older.
  • Patient must be scheduled for a total thyroidectomy, which is a surgery to remove the entire thyroid gland, for any reason.
  • Patient must provide written informed consent, meaning they agree to participate in the study after being fully informed about it.
  • Patient must be affiliated with the social security system.

Who cannot join the trial?

6 criteria

  • Patients who have not had their thyroid gland removed (thyroidectomy).
  • Patients who are not experiencing low calcium levels in the blood after surgery (post-operative hypocalcemia).
  • Patients who are not taking vitamin D supplements (cholecalciferol) before surgery.
  • Patients who are not within the specified age range for the study.
  • Patients who are not male or female, as both genders are included in the study.
  • Patients who belong to a vulnerable population, which means they might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Cholecalciferol is a form of vitamin D that is often used to help the body absorb calcium. In this clinical trial, patients are given cholecalciferol before undergoing thyroid surgery. The goal is to see if taking this vitamin can help prevent low calcium levels in the blood, which can sometimes happen after the surgery. By boosting vitamin D levels before the operation, doctors hope to reduce the risk of this complication and improve recovery for patients.

What is already known about the treatment

Cholecalciferol – Cholecalciferol is administered orally and is commonly used as a vitamin D supplement. It is currently recognized in medical literature for its role in addressing vitamin D deficiency, which can lead to various health issues. The main therapeutic indication for cholecalciferol in this context is to prevent or treat hypocalcemia, a condition characterized by low calcium levels in the blood, particularly after thyroid surgery. At the molecular level, cholecalciferol helps increase calcium absorption in the intestines, thereby raising blood calcium levels. It is classified pharmacologically as a vitamin D analog.

Investigated diseases

Hypocalcemia – Hypocalcemia is a condition characterized by low levels of calcium in the blood. It often occurs after thyroid surgery, such as a thyroidectomy, due to potential damage or removal of the parathyroid glands, which regulate calcium levels. The condition can lead to symptoms like tingling in the fingers, muscle cramps, and spasms. In more severe cases, it can cause numbness around the mouth and in the extremities, as well as muscle stiffness. The progression of hypocalcemia can vary, with symptoms appearing shortly after surgery and potentially lasting for several days. Monitoring calcium levels is crucial to manage and understand the progression of this condition.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-516793-30-00Protocol codeCHRD2115Estimated enrolment200 patientsSponsorHopital NOVO

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).